Malfroid 1978.

Methods	Randomisation: “assigned at random”. Blinding: double‐blind. Duration: 4 weeks. Design: parallel Location: not indicated. Setting: not indicated.
Participants	Diagnosis: paranoid schizophrenia (N = 12), catatonic schizophrenia (N = 9), chronic psychosis (N = 3). N = 24. Gender: 24M. Age: mean 48.6 years. History: duration stable: not indicated, duration of illness: mean 25.3 years, number of previous hospitalisations: not indicated, age at onset: not indicated, severity of illness: not indicated, baseline antipsychotic dose: not indicated.
Interventions	1. Haloperidol: fixed/flexible dose: not indicated, dose range: not indicated, mean dose: 6‐8 mg/day. N = 12. 2. Bromperidol: fixed/flexible dose: not indicated, dose range: not indicated, mean dose: 4‐8 mg/day: N = 12. Rescue medication: anticholinergics were allowed.
Outcomes	Examined: Clinically important response to treatment: Global efficacy scale. Adverse effects: dyskinesia, use of antiparkinson medication, hypotension. Unable to use: Mental state general: Psychiatric rating scale (designed by the “Wirtschafts‐Mathematik Zürich”) (no raw data available).
Notes	Study participants were 24 “chronic psychotic patients”. “Before the trial period, all patients were on a maintenance neuroleptic treatment”. No participant with first‐episode schizophrenia was enrolled.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	“Randomly assigned”. No further details.
Allocation concealment (selection bias)	Unclear risk	No further details.
Blinding (performance bias and detection bias) (performance bias)	Unclear risk	“Double‐blind”. No further details.
Blinding (performance bias and detection bias) (detection bias)	Unclear risk	“Double‐blind”. No further details.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	The study did not address this outcome; insufficient information to permit judgment concerning incomplete outcome data.
Selective reporting (reporting bias)	High risk	Outcome data were not fully addressed (no raw data for the psychiatric rating scale). Adverse effects reporting was incomplete. BPRS is mentioned in the abstract but no results were presented.
Other bias	High risk	“Before the trial period, all patients were on a maintenance neuroleptic treatment.”